Caricamento...
Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma?
INTRODUCTION: In metastatic renal cell carcinoma (mRCC), the bone is the second most common site of metastasis and is associated with increased morbidity and poorer quality of life. Bone-targeted therapies (BTTs) such as denosumab and zoledronic acid may prevent skeletal-related events (SREs). Howev...
Salvato in:
| Pubblicato in: | Transl Oncol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Neoplasia Press
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6931200/ https://ncbi.nlm.nih.gov/pubmed/31869748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.009 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|